Browse drugs

…e of pathogenic ASCs and sustain low disease activity following daratumumab treatment.…

…oncerns, we developed a trial to evaluate the administration of daratumumab at home for patients with MM.Research design and methods We com…

… (14.8%), nintedanib (11.3%), ibrutinib (10%), azacitidine, and bosentan (7.8%). OD distribution by ATC group was dominated by L (n=19),…

…s conducted including NDMM patients aged ≥80 years treated with daratumumab from its introduction until January 2025. Baseline variables in…

…Daratumumab is a monoclonal antibody targeting CD38 and is widely used in t…

…Background and Importance Daratumumab in combination with lenalidomide-dexamethasone (DR-d) is consid…

…ds, and anti-CD38 monoclonal antibodies such as daratumumab and isatuximab. CD38 is expressed at high levels in the hematopoietic system, …

… allogeneic CAR T cells.References Casneuf T, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in rela…